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INTRODUCTION 
“For all the happiness that mankind can gain  
It is not in pleasure but in relief from pain” 
                                                                         -    JOHN DYRDEN  
“Pain, like pleasure is passion of the soul,  
                  That is an emotion and not one of the senses” 
                                       -    PLATO and ARISTOTLE (375 B.C) 
       Pain is a fundamental biological phenomenon. The International 
Association for the Study of pain has defined pain as an unpleasant 
sensory and emotional experience associated with actual or potential 
tissue damage. Pain is always underestimated and under treated. The 
relief of pain during surgery is the main part of anaesthesia. 
In 1784 James Moore used mechanistic concepts to promote 
neural compression as a useful technique for the provision of 
surgical anaesthesia. 
       In 1855, neurologic pain can be treated by circum-neural 
injection of pain relieving drug. At the same year Gadecke (German) 
isolated of alkaloid from leaves of coca plant. In 1860 Albert 
Nieemann was successful in isolating and naming the alkaloid from 
the leaves of erythroxylon coca. 
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        In 1884 idea of injecting cocaine into nerve trunk introduced by 
William Halsted and Alfred Hall. After that Heinrich F Braun found 
that adding epinephrine to cocaine prolong the effect of local 
anaesthetics. But later 1911 G.Hirschel performed first percutaneous 
axillary brachial plexus block. 
In 1911 Kullenkampff introduced the classic supraclavicular 
approach of brachial plexus block.  Winnie and Collins introduced 
the subclavian perivascular approach of brachial plexus block. 
Moorthy introduced the modified lateral paravascular approach. 
With introduction of barbiturate and cyclopropane, the enthusiasm 
for block anaesthesia waned in early 1940s. In current recent years 
however, the technique has had resurgence, due in large part to 
increased understanding of neural plasticity and the possibility of 
minimizing hospital stay length by effective use of regional block 
anaesthesia. 
               Several techniques have been used to prolong the duration 
of regional anaesthesia. Besides the continuous infusion of local 
anaesthetics through catheters and recently opioids as adjuvants to 
local anaesthetic solutions, the addition of epinephrine appears to be 
the most widely used. The prolongation of action is generally related 
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to local vasoconstriction which slows down the vascular absorption 
of local anaesthetics. Vasoconstriction is related to the action of 
epinephrine on alpha-type receptors. Nevertheless, this action 
remains controversial and other mechanisms have been proposed. 
The existence of alpha-type receptors, which take part in the 
transmission of nociceptive stimuli at the spinal level, emphasizes a 
possible direct action of alpha-adrenergic agonists on neural tissues. 
These receptors are of the Alpha-2 type. Several experimental and 
clinical studies have shown that Alpha-2 adrenergic agonists like 
clonidine were able to prolong sensory and motor blockade. 
         This study involves the addition of an alpha-2 adrenergic 
agonist, Clonidine to local analgesic solution in supraclavicular 
approach to brachial plexus block and the effects are evaluated and 
compared with brachial plexus block   using local analgesic solution 
and adrenaline  
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AIM OF THE STUDY 
 
 To compare the effectiveness of Clonidine and adrenaline as 
adjuvants to bupivacaine in supraclavicular approach to Brachial 
plexus block for prolonging the duration of post operative analgesia 
and prolonging the motor blockade. 
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HISTORY 
 
1. 1858-  theory of pain was a separate and distinct sense was 
definitely formulated by Mortiz S.Schiff 
2. 1884-William Halsted  and Alfred Hall – idea of injecting 
cocaine into nerve trunk 
3. 1911- G. Hirschel performed  first percutaneous axillary 
brachial plexus block 
4. 1911- D.Kulenkampff performed supraclavicular brachial 
plexus block 
5. 1943- Lidocaine was synthesized by Lofgreen and 
Lundquvisit 
6. 1956- Bupivacaine synthesized by Ekenstam 
7. 1963- Bupivacaine introduced clinical practice by Telivuo 
8. Melzock and Walts (1965) propounded the Gate Control 
Theory of pain. 
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ANATOMICAL CONSIDERATIONS 
 
 Knowledge of the formation of the brachial plexus and of its 
distribution is essential to the intelligent and effective use of the 
brachial plexus block for the surgeries in the upper limb. Close 
familiarity with the vascular, muscular and fascia relationship of the 
plexus throughout the formation and distribution is equally essential 
to the mastery of various techniques of Brachial plexus Blockade. 
Derivation of plexus: 
 The brachial plexus is derived from the anterior primary rami 
of the fifth, sixth, seventh, eighth cervical nerves and 1st thoracic 
nerve, with variable contributions from the Fourth cervical (pre 
fixed) and second thoracic nerves (post fixed). 
COURSE: 
 After leaving their intervertebral foramina, the roots course 
anterolaterally and inferiorly to lie between the anterior and middle 
scalene muscles, which arise from anterior and posterior tubercles of 
cervical vertebrae respectively. Here unite to form the trunks. 
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  C5               
Æ   Superior trunk  
  C6 
  C7       Æ  middle trunk  
  C8  
 Æ      Inferior trunk 
  T1 
 The prevertebral fascia invests both the anterior and middle 
scalene muscles, fusing laterally to enclose the brachial plexus in a 
fascial sheath. Trunks emerge from the lower border of the muscle 
running inferiorly and anterolaterally covering towards the upper 
border of the 1st rib, where they lie cephaloposterior to the 
subclavian artery. 
 At the lateral edge of the 1st rib each trunk divides into anterior 
and posterior divisions passing inferior to mid portion of clavicle. 
They reunite within the axilla to form the lateral, medial and 
posterior cords and related to the second part of the axillary artery. 
The anterior divisions from upper and middle trunk unite to form the 
lateral cord. The posterior divisions from all three trunks unite to 
form the posterior cord. The anterior divisions from the lower trunk 
continue as the medial cord. 
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 At the lateral border of the pectoralis minor, the three cords 
divide into the peripheral nerves of the upper extremity.  
Lateral cord:- 
i. Lateral root of median nerve 
ii. Lateral pectoral nerve 
iii. Musculocutaneous nerve  
Medial cord:       
i. Medial root of median nerve  
ii. Medial cutaneous nerve of  arm  
iii. Medial cutaneous nerve of forearm 
iv. Medical pectoral nerve 
v. Ulnar nerve 
Posterior cord:  
i. Radial nerve 
ii. Axillary nerve 
iii. Upper and lower subscapular nerve  
iv. Nerve to latissimus dorsi  
Branches from roots 
i. Dorsal scapular nerve to Rhomboid muscles(C5)  
ii. Nerve to serratus anterior (C5, C6, C7) 
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Branches from trunk: 
i. Nerve to subclavius (C5-C6) 
ii. Supra scapular  nerve (C5-C6)  
RELATIONS: 
 Brachial plexus has its roots between the scalene muscles, 
trunks in the posterior triangle of the neck, divisions behind the 
clavicle and cords at the level of the Axilla and nerves beyond the 
axilla. In the course it lies superior and posterior to the subclavian 
artery. Dome of pleura is anteromedial to the lower trunk and 
postermedial to the subclavian artery .The trunks emerge between 
the fascia covering the anterior and middle scalene muscles. 
 
TECHNIQUE OF BLOCKADE; 
SUPRACLAVICULAR APPROACH TO BRACHIAL PLEXUS 
BLOCKADE 
Classic approach: 
Anatomical landmarks: The three trunks are clustered 
vertically over the first rib cephaloposterior to the subclavian artery. 
Neurovascular bundle lies inferior to the clavicle at about its 
midpoint. 
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POSITION OF THE PATIENT: 
 Patient is placed in a supine position with the head turned to 
opposite side from the side to be blocked. The arm is pushed down 
to depress the clavicle. 
TECHNIQUE: 
 The midpoint of clavicle is identified and marked. The 
posterior border of sternocleidomastoid is felt, by asking the patient 
to raise the head while keeping the head turned to opposite side. The  
interscalene groove is palpated by rolling the fingers back from the 
posterior border of the lower end of the strenocleidomastoid  muscle 
over the anterior scalene muscle. 
 The anterior and middle scalene muscles can be highlighted by 
asking the patient to inspire vigorously. A mark is made in the 
groove 1.5 to 2 cm above the midpoint of clavicle, palpation of 
subclavian artery confirms this landmark. On the right side, 
interscalene groove is palpated with the left index finger and the 
needle is inserted with the right hand and reversing the hands for the 
left side. 
 After appropriate preparation of aseptic measures and 
intradermal wheel, a short bevelled   22gauge 3.5 -4 cm long needle 
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is inserted at the marked point. Subclavian artery is guarded with 
thumb, the needle is directed caudally, posteriorly and slightly 
medially until paraesthesia is elicited or first rib is encountered. 
Needle enters the Fascial sheath 1-2cm deep to the skin 
approximately. Marked resistance will give way to pop as the fascia 
is pierced and paraesthesia may occur. 
  The needle is held firmly and then the local analgesic solution 
is injected after careful aspiration to exclude intravascular 
placement. If needle is in the subclavian artery just take the needle 
out and direct the needle posterolaterally to elicit paresthesia. 
 If the first rib is encountered without elicitation of 
paraesthesia, the needle is systematically walked over the rib until 
the plexus or subclavian artery is located. The rib is contacted at a 
depth of 3-4 cm. The solution should flow without resistance. High 
resistance or pain on injection may indicate intraneural injection and 
the needle must be repositioned. 
 Volume of local anaesthetic (either 1% lignocaine or 0.25% 
bupivacaine) that can be used is 25-40 ml depending on the weight 
of the patients. When large volumes are used the sheath may be felt 
to distend during injection and is easily distinguished from the 
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subcutaneous swelling of an extra fascial injection. To encourage the 
spread proximally, digital pressure distal to the needle point may be 
used and digital pressure proximal to needle insertion point may help 
to encourage distal spread. 
 Complications: 
i. Supraclavicular approach has the highest risk of 
pneumothorax 0.5-6% when compared to other techniques. 
Majority of pneumothorax takes 24 hrs to develop and 
rarely develop in short duration. Tall thin patients with high 
apical pleura are prone to develop pneumothorax in shorter 
duration. Incidence of pneumothorax reduced by avoiding 
multiple probing and by using small needles. 
ii.  Unilateral Phrenic nerve block can occur but has no 
significance 
iii. Horner syndrome – occurs when large volume is used, 
resolves spontaneously  
iv. Unintentional  intravascular injection 
v. Stellate ganglion block and recurrent laryngeal nerve 
palsies (very rare) 
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Physiological considerations 
International association for the study of pain has defined pain 
as “Unpleasant sensory and emotional experiences associated with 
actual or potential tissue damage are defined in terms of such 
damage”. 
 Pain perception requires noxious stimuli is encountered .It is 
transformed from its native form by the activated nociceptors into 
electrical signals which are then transmitted along the corresponding 
nociceptive fibres. These fibres in turn synapse onto second order 
neurons in the spinal cord. These interneurons are located in the 
dorsal horn. It is at these interneurons where the initial modulation 
of nociceptive input occurs. From the spinal cord nociceptive input 
is transmitted to the brain stem, thalamus and cortex. 
 Peripheral neuroanatomy of nociception 
C and Aδ fibres are the main peripheral nociceptors. The skin 
joints and periosteum are richly innervated with C and Aδ 
nociceptors as well as the non nociecptive AB sensory fibres. 
 Aδ are responsible for the sensation of first pain, the initial 
sharp pain experienced following an injury. C fibres are 
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unmyelinated and are responsible for second pain, the slowly 
building throbbing burning pain experienced following an injury. 
Classification of sensory fibres 
Sensory 
receptors 
Speed of 
transmission
Sensory function Myelination 
C fibres 0.5 – 2 m / 
sec 
Noxious chemical, 
mechanical, thermal 
activation (slow 
burning second pain) 
Unmyelinated
A-Alpha 
fibres 
70 – 120 m / 
sec 
Noxious chemical 
thermal, mechanical 
stimuli, (sharp fast, first 
pain) 
Lightly 
myelinated 
A-Beta  
Fibres 
30 – 70 m / 
sec 
Non painful, light 
touch,pressure, 
vibration 
proprioception 
Heavily 
myelinated 
A-Gamma 
fibres 
30 – 70 m / 
sec 
Proprioception / Motor 
to muscle spindle 
myelinated 
A-Delta 
Fibres 
12 – 30 m / 
sec 
Pain, cold, touch myelinated 
B fibres 3 – 15 m / 
sec 
Pre ganglionic 
autonomic 
(sympathetic) 
myelinated 
Peripheral neurochemistry and neurotransmitters: 
  Commonly released inflammatory mediators implicated in 
pain and hyperalgesia include Bradykinins, potassium, substance P 
cytokines, histamine, serotonin, prostaglandins. These peripheral 
neurotransmitters either activate or sensitise the peripheral 
nociceptors to pain.  
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Peripheral neuro chemistry Algogenic Agents: 
Algogenic Agent Action on nociceptors 
Bradykinin Activates 
Substance P Sensitizes 
Potassium Activates 
Hydrogen Activates 
Arachidonic acid Sensitizes 
Cytokines Sensitizes 
Serotonin Sensitizes 
Nor adrenaline High concentration activates 
and sensitizes after injury. 
 
Peripheral alpha 2 receptors: 
          Alpha 2 adrenoreceptors are located on primary afferent 
terminals, on neurons in the superficial laminae of the spinal cord, 
and within several brainstem nuclei implicated in analgesia, 
supporting the possibility of analgesic action at peripheral, spinal, 
and brainstem sites. 
          Clonidine enhances both sensory and motor blockade from 
peripheral nerve injection and epidural / spinal injection of local 
anaesthetics. 
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           Clonidine blocks conduction of C and A gamma fibers and 
increases potassium conductance in isolated neurons and intensifies 
conduction block of local anaesthetics.  
            Local vasoconstriction resulting in reduced absorption from 
injection site was another point of discussion, but compared with 
adrenaline as adjuvant it failed to influence plasma levels, indicating 
a direct action on nerve.   
Pain pathways 
SPINAL CORD  
 The gray matter of the spinal cord is divided into ten lamina 
with lamina I-IV representing the dorsal horn. The dorsal horn is 
capped by the Lissauer’s tract which consists of branches of 
cutaneous Aδ and C-fibres and few visceral afferents. 
 Nociceptive fibres terminate in the superficial layers of lamina 
1 & II while the non-painful myelinated fibres terminate in the 
deeper layers of lamina III, IV. Lamina II has the highest 
concentration of opioid receptors in the spinal cord. Modulation and 
inhibition of nociception may occur at this level through the use of 
opioids (systemic and neuraxial) 
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ASCENDING SENSORY PATHWAYS 
 Peripheral sensory neurons synapse onto the secondary 
interneurons of the dorsal horn. The axons of the non nociceptive 
secondary neurons travel isobilateral in the dorsal columns of the 
spinal cord as fasciculus cuneatus (upper body through T6) and 
fasciculus gracilis  (lower body below T6) and synapse in thalamus. 
 The axons of the nociceptive secondary neurons after 
synapsing, travel contra laterally in the anterolateral aspects of the 
spinal cord as the neospinothalamic and paleospinothalamic tract. 
 Neospinothalamic tract carries fine discrimination of pain eg. 
Location,  intensity, and first pain. 
Paleospinothalamic tract responds to noxious stimuli. The 
paleo spinothalamic tract synapses in the thalamus, hypothalamus 
and limbic system and plays a role in emotional aspects of pain via 
limbic system. The thalamus has multiple connections to limbic 
system and cortex. 
DESCENDING INHIBITORY PATHWAYS 
 The descending controls of pain project specifically onto 
laminas I, II,V of the dorsal horn from mesencephalon, raphenuclei 
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and reticular tract. The mesencephalon is rich in opioid receptors. 
This area sends excitatory transmissions to the rostroventral  medulla 
which sends nordrenaline and seratonin inhibitory tracts via the 
dorsolateral funiculus to lamina I,II,V of spinal cord. 
 The noradrenaline and serotonin fibres meditate transmission 
between the primary afferents and the secondary neurons of the 
dorsal horn. Increased activity of these fibres leads to increased 
inhibition of pain transmission. 
Location of Alpha 2 receptors;  
              Primary afferent terminals, on neurons in the superficial 
laminae of spinal cord and brainstem nuclei.  
Location of opioid receptors (central); 
 Opioid receptors are found in the various regions in CNS 
namely, cerebral cortex, limbic cortex (anterior and posterior 
amygdale, hippocampus, hypothalamus, medial thalamus, mid brain, 
periaqueductal gray matter, extrapyramidal areas, substantia 
gelatinosa and sympathetic preganglionic neurons. 
Opioid receptors are also found in the cardiac sympathetic 
fibres, cardiac branches of vagus, adrenal medulla, and the gastro 
intestinal tract. 
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PHARMACOLOGY 
BUPIVACAINE; 
  Bupivacaine is an amide linked local anaesthetic. It is a 
hydrochloride salt of 1-butyl-N-(2, 6-dimethylphenyl) piperidine-2- 
carboxamide and is presented as a racemic mixture. 
¾ It was synthesized by Ekenstam in 1957. 
¾ First report of its use was published in 1963 by Telivuo. 
¾ It is derived from Mepivacaine and is very stable compound 
and may be autoclaved repeatedly. 
Pka      -  8.1 
Molecular weight   -  288  
Protein binding    -  95% 
Lipid solubility   -  28 
Elimination half life  -  210 minutes 
Toxic plasma concentration -  >1.5μg/ml 
Approximate duration of action -  175minutes 
Availability: 
 Ampoules - 0.5% Bupivacaine hydrochloride with dextrose  
(Heavy) 4cc 
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- 0.5% Bupivacaine hydrochloride (lain) 
          Vials  - 0.25% and 0.5% Bupivacaine hydrochloride 20cc 
 Dosage - Maximum dosage 3mg/kg body weight. 
Uses: 
¾ Spinal anaesthesia 
¾ Epidural anaesthesia 
¾ Caudal anaesthesia 
¾ Continuous epidural anaesthesia 
¾ Peripheral nerve block 
Onset time and duration of action 
Site of action Onset (minutes) Duration (minutes) 
Intrathecal  5 90-120 
Epidural 15-20 165-225 
Brachial plexus 10-20 600 
 
Pharmacokinetics: 
 Once injected intrathecaly, it gets absorbed by the nerve 
rootlets and results in the desired effect. It is rapidly absorbed from 
the site of injection, but the rate of absorption depends on the 
vascularity at the site and presence of vasoconstrictors. 
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 High lipid solubility of bupivacaine makes it easy for nerve 
and vascular tissue penetration. 
 80-95% of the absorbed bupivacaine binds to the plasma 
proteins. 
Distribution: 
 Rapid distribution phase: (α) 
 In this phase the drug is distributed to highly vascular region 
t½ of α - being 2.7 minutes.      
 Slow disappearance phase: (β) 
 In this phase the drug is distributed to slowly equilibrating 
tissues t1/2 of β – being 28minutes.  
 Biotransformation and excretion phase:  (δ)  
 T1/2 of δ is 3.5hours. Clearance is 0.47 litre/ minute. 
Biotransformation: 
 Possible pathways of metabolism of bupivacaine include 
aromatic hydroxylation and conjugation. Only the N-dealkylated 
metabolite, N-desbutyl bupivacaine has been measured in blood (or) 
urine after epidural (or) spinal anaesthesia. Alpha-1 acid 
glycoprotein is the most important plasma protein binding site of 
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bupivacaine and its concentration is increased by many clinical 
situations including post operative trauma. 
Excretion: 
 It is through the kidney, 4-10% of the drug is excreted 
unchanged. 
Mode of Action: 
a) Site of action: 
i) Peripheral nerve rootlet , fine nerve filaments 
ii) The spinal nerve rootlet fine nerve filaments having a large 
surface area are exposed to the local anaesthetics 
iii) Posterior and lateral aspects of the spinal cord itself.  
b) Sodium Channel blockade: 
 They impede sodium ion access to the axon interior by 
occluding the transmembrane sodium channels thus delaying the 
process of depolarization and axon remains polarized. It is a non-
depolarization blockade.     
Pharmacodynamics: 
 It has got a longer duration of action but a slower onset. 
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Cardio vascular system: 
 It depresses myocardial automaticity (spontaneous phase iv 
depolarization) and reduce the duration of the refractory period. 
Myocardial contractility and conduction velocity are also depressed 
at high concentrations. It causes some degree of arteriolar 
vasodilatation. The ensuing combination of bradycardia, heart block, 
and hypotension may culminate in cardiac arrest. 
 
Respiratory System: 
         It relaxes bronchial smooth muscle. Apnea can results from 
phrenic and intercostal nerve paralysis or depression of the 
medullary respiratory center following direct exposure to drug. 
Toxicity: 
 Toxicity is related to plasma level of unbound drug and more 
likely due to an inadverdant intravenous injection. Systemic toxicity 
reactions primarily involve central nervous system and cardio 
vascular system. The blood level required to produce central nervous 
system toxicity is less than that required to produce circulatory 
collapse.  
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Central Nervous System Toxicity:    
 Early symptoms are circumoral numbness, tongue paresthesia, 
and dizziness. Sensory complaints include tinnitus and blurred 
vision. Excitatory signs (eg, restlessness, agitation, 
nervousness,paranoia) often precede central nervous system 
depression (eg, slurred speech, drowsiness, unconsciousness). 
Muscle twitching heralds the onset of tonic clonic seizures. 
Respiratory arrest often follows. The excitatory reactions area result 
of selective blockade of inhibitory pathways. 
Cardiovascular System Toxicity: 
 The rate of depolarization in fast conducting tissue of purkinje 
fibres and ventricular muscle is decreased. The rate of recovery of 
bupivacaine induced block is slower than that of lignocaine. 
Extremely high concentration of the drug causes sinus bradycardia, 
hypotension, atrioventricular heart block, idioventricular rhythms, 
and life threatening arrhythmias such as ventricular tachycardia, 
ventricular fibrillation and cardiac arrest. 
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                         CLONIDINE HYDROCHLORIDE 
Introduction:  
             Clonidine hydrochloride is a centrally acting selective partial 
alpha -2 agonist introduced in early 1960s, it was during its use as a 
nasal decongestant that its anti- hypertensive property was found 
out. Subsequently more insights into the pharmacological properties 
has led to its use in clinical anaesthesia practice as well.  
          Clonidine hydrochloride is an imidazoline compound and  
exists as a mesomeric compound. The chemical name is 2-(2,6- 
dichlorophenylamino)-2-imidazoline hydrochloride. The structural  
formula is C9H9C12N3HCl. 
        The molecular weight is 266.56. Clonidine is an  odourless, 
bitter, white, crystalline substance, soluble in alcohol and water. 
Clonidine improves the quality of anaesthesia, provides a more 
stable cardiovascular course during anaesthesia, presumably because 
of their Sympatholytic effect and need for lower dose of cardioactive 
anaesthetic and reduces the dose requirement of the anaesthetic 
agent. Clonidine may reduce the halothane MAC by upto 50% in a 
dose dependent manner.  Clonidine potentiates the anaesthetic action 
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of the local anaesthetics with fewer side effects in peripheral nerve 
blocks and central neuraxial blockade. 
Availability:          
        Available as one ml ampoule containing 150 micrograms.It 
should be stored below 25oc.  
Mechanism of action: 
        Clonidine is a centrally acting selective partial α2 adrenergic 
agonist with a selectivity ratio of 220: 1 in favour of α2 receptors.  
The three subtypes of α2 receptors are α2a, α2b, α2c. α2a receptors 
mediate  sedation, analgesia,  sympatholysis. α2b receptors mediate 
vasoconstriction and anti- shivering. The startle response may reflect 
the activation of α2c receptors.   The drug is lipid soluble, penetrates 
the blood brain barrier to reach the hypothalamus and medulla when 
injected epidurally.  It stimulates the inhibitory α2 adrenoreceptors 
to reduce the central neural transmission in the spinal neurons.  
Inhibition of substance- P release is believed to be involved in the 
analgesic effect.  
  The α2 adrenoreceptors are located on the afferent terminals of 
both peripheral and spinal neurons in the superficial laminae of the 
spinal cord and within several brain stem nuclei implicated in 
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analgesia.  The superficial laminae contain three groups of neurons: 
tonic, adapting, single- spike firing, all of which receive their 
primary sensory input from Aδ and C fibres. Clonidine inhibits 
voltage gated Na+ and K+ channels and suppresses the generation of 
action potentials in tonic- firing spinal dorsal horn neurons, 
contributing to analgesic effect. The ability of clonidine to modify 
the function of potassium channels in the CNS (cell membrane 
become hyperpolarized) may be mechanism for profound decrease 
in anaesthetic requirements.  
            Another contribution to analgesic effect may be through the 
 release of acetylcholine in the neuraxial region. The α2 adrenergic  
agonists also enhance analgesia from intraspinal opioids. Sedation is  
produced by its action on locus ceruleus.  
         Clonidine affects the blood pressure in a complex fashion after 
neuraxial or systemic administration because of opposing action at 
multiple sites.  In the nucleus tractus solitarius and locus ceruleus of  
the brain stem, activation of post- synaptic α2 adrenoreceptors 
reduces sympathetic drive. It also activates nor-adrenergic 
imidazoline preferring binding sites in the lateral reticular nucleus 
producing hypotension and anti- arrythmogenic action. In the 
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periphery it acts on pre-synaptic α2 adrenoreceptors at sympathetic 
terminals reduces the release of nor-epinephrine causing 
vasorelaxation and reduced chronotropic drive. The brainstem and 
the peripheral effects of α2 adrenoreceptor stimulation are 
counterbalanced by the direct peripheral vasoconstriction through its 
action on α2 adrenoreceptors from the circulating concentrations of 
clonidine. 
           Sedation is a desired property. Clonidine produces a dose 
dependent sedation at the dose of 50 micrograms or more in less 
than 20  
minutes regardless of the route of administration. 
Clonidine doesn’t induce profound respiratory depression even 
after massive overdose nor do they potentiate respiratory depression 
from opioids. 
In peripheral nerves it produces a minor degree of blockade at 
high concentrations with some preference for C- fibres in the 
peripheral nerves and this effect in part enhance the peripheral nerve 
block when added to local anaesthetics, probably because the 
α2adrenoreceptors are lacking on the axons of peripheral nerves. 
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Pharmacokinetics; 
           Clonidine is well absorbed orally and is nearly 100% bio 
available and reaches peak plasma concentration with in 60 to 90 
minutes. The mean half life of the drug in plasma is about 9 to 12 
hours, with approximately 50% metabolized in the liver whereas is it 
is excreted in an unchanged form by the kidney, and its half- life can 
dramatically increase in the presence of impaired renal function.  
 A transdermal delivery system is available in which the drug is  
released at a constant rate for about a week. Three or four days are  
required to achieve steady state concentration. 
        Clonidine is highly lipid soluble and readily distributes into 
extra- vascular sites including the central nervous system. 
 300 micrograms intravenously over 10 min produces: 
    Distribution t ½    :    11 ± 9 minutes. 
    Elimination t½  :   9 ± 2 hour, 41 hours in severe  
          Renal dysfunction. 
    Volume of distribution : 2.1 ± 0.4 l/kg 
    Plasma protein binding  : 20-40 % in vitro. 
    Metabolism   :  minor pathways with the major  
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        Metabolite, p- hydroxyclonidine. 
  Excretion:  
70% of the dose, mainly in the form of unchanged parent drug 
(40-60%) in urine. 
             So, the elimination t1/2 of clonidine varies as a function of 
 creatinine clearance.  In subjects undergoing hemodialysis only 5% 
of the body clonidine store was removed. 
Dosage regimen;  
        Oral                    - 3-5 μg/kg 
        Intramuscular     - 2 μg/kg 
        Intravenous        - 1-3 μg/kg 
       Spinal                   - 50-100 μg 
       Epidural               -1-2 μg/kg 
      Transdermal          - 0.1- 0.3 mg released per day  
 
Precautions: 
1. In patients with renal insufficiency, lower dose is needed.  
2.  Sudden withdrawal of prolonged continuous epidural infusion 
 produces hypertensive crisis. So it should be gradually 
discontinued over 2 to 4 days. 
 36
3. Use with caution in patients with cerebrovascular or coronary 
insufficiency. 
4. If a patient with beta blocker is on continuous epidural 
therapy, beta blocker should be withdrawn several days 
before discontinuation of epidural clonidine. 
5. Intrathecal / epidural clonidine often causes bradycardia that if 
symptomatic can be treated with inj. Atropine. 
Contraindications: 
1. Known hypersensitivity to clonidine or components of the 
 product. 
2. In patients with brady arrhythmia or AV block. 
3. Patients with severe cardiovascular disease 
4. Patients with cardiovascular / hemodynamic instability. 
Interactions:    
1. Clonidine may potentiate the CNS- depressive effect of 
alcohol, barbiturates or other sedative drugs. 
2. Narcotics may potentiate the hypotensive effects of clonidine. 
3. Tricyclic anti depressants may antagonize the hypotensive 
effects of clonidine. 
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4.  Concomitant administration of drugs with a negative 
chronotropic/ dromotropic effect (beta blockers, digoxin) can 
cause or potentiate bradycardiac rhythm disturbances. 
5. Beta blockers may potentiate the hypertensive response seen 
with clonidine withdrawal. 
6.    Epidural clonidine may prolong the duration of pharmacologic 
effects of epidural local anaesthetics, opioids, neostigmine and other 
drugs.  
USES: 
1.    Preanaesthetic Medication; 
            Oral clonidine  Preanaesthetic medication (5 μg/kg )          
(a) blunts reflex tachycardia associated with direct laryngoscopy for 
intubation of trachea, (b) decrease intraoperative lability of blood 
pressure and heart rate, (c) decrease plasma catecholamine 
concentrations, and (d) dramatically decrease anaesthetic 
requirements for inhaled  and injected drugs.  Clonidine also 
attenuates the rise in intraocular pressure associates with 
laryngoscopy and intubation.  
2. Epidural block:  Clonidine as a sole agent or in combination 
with opioids or local anaesthetics to provide excellent 
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analgesia in labour analgesia. Epidural clonidine is also 
indicated for the treatment intractable pain, which is 
unresponsive to maximum dose of oral or epidural opioid, as 
do patients with reflex sympathetic dystrophy, neuropathic 
pain.  
3. Spinal anaesthesia: Clonidine combined with local 
anaesthetics improves the quality and duration of the block, 
minimize the tourniquet pain during lower limb surgery, and 
prevents shivering. 
4. Caudal anaesthesia: clonidine combined with local 
anaesthetics increases the duration of anaesthesia and 
analgesia by 2 or 3 times without hemodynamic side effects. 
Dose 2-3 μg/kg 
5. Peripheral nerve blocks: Clonidine prolongs the duration of 
anaesthesia and analgesia with local anaesthetics by two times 
in a dose of 75 to150 micro grams. 
6. Bier’s block: 150 microgram of clonidine enhances the    
tolerance of tourniquet                                            
7.  It is also used in intra articular analgesia. 
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8.     Protection against perioperative myocardial ischemia; clonidine       
decreases myocardial ischemia, infarction and mortality following 
cardiovascular surgery.  
9.     To treat hypertensive crises 
10. Diagnosis of pheochromocytoma; clonidine, 0.3 mg will 
decrease the plasma concentrations of catecholamine in normal 
patients but not in the presence of pheochromocytoma. 
11.  Treatment of shivering; Administration of clonidine, 75 μg IV 
stops   shivering by inhibit thermoregulatory control. 
12.   Treatment of opioid and alcohol withdrawal syndrome;     
Side effects; 
1. The most common side effects are sedation and xerostomia.  
2. Cardiovascular complaints are bradycardia, hypotension, and 
ECG abnormalities like sinusnode arrest, junctional bradycardia; 
high degree AV block and arrhythmia are reported rarely. 
Occasionally require treatment of bradycardia with I.V 
anticholinergics.   Orthostatic hypotension occurs rarely. 
3. Rebound hypertension; Abrupt discontinuation of clonidine can 
result in rebound hypertension as soon as 8 hours and as late as 36 
hours after the last dose. Symptoms of nervousness, diaphoresis, 
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headache, abdominal pain, and tachycardia often precede the actual 
increase in systemic blood pressure. Labetalol is useful in treatment 
of rebound hypertension. 
4.  Skin rashes are occurs frequently. 
5.  Impotence occurs occasionally.   
Over dosage and treatment: 
        There is no specific antidote for clonidine overdosage. 
Supportive measures like atropine, ephedrine, and i.v fluids are 
enough.   
          Yohimbine partially reverses the analgesia and sedation but 
not the BP and heart rate changes produced by the epidural 
clonidine. 
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ADRENALINE (EPINEPHRINE) 
 
Adrenaline is the prototype drug among the 
sympathomimetics. Its natural function on release from adrenal 
medulla, include regulation of a) myocardial contractility b) heart 
rate c) vascular and bronchial smooth muscle tone d) Glandular 
secretion e) Metabolic processes such as glycogenolysis and 
lipolysis.  It is the most potent activation of alpha adrenergic 
receptors, being two to ten times more active than isoproterenol. 
Adrenaline also activates beta 1 and beta 2 receptors.  
Adrenaline – α1 + α2 +β1 + β2 + weak β3 action. 
Pharmacokinetics: 
 Oral administration is not effective because adrenaline is 
rapidly metabolized in gastrointestinal mucosa and liver by MAO 
and COMT present in intestinal wall and liver.  Therefore adrenaline 
is administered SC or IV.  Absorption after SC injection is slow 
because of local adrenaline induced vasoconstriction.  Adrenaline is 
poorly lipid soluble, preventing its ready entrance into the CNS and 
accounting for the lack of cerebral effects. 
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Clinical Uses: 
a) Addition to local anaesthetic solution to decrease systemic 
absorption and prolong the duration of action of local 
anaesthetics.  (5 µg/ml of local anaesthetics) 
b) Treatment of life threatening allergic reactions. 
c) Administration during cardio pulmonary resuscitation as the 
single most important therapeutic drug. 
d) Continuous infusion to increase myocardial contractility. The 
administration of supraphysiologic doses (100µg/kg) of 
adrenaline during cardiopulmonary resuscitation has not been 
shown to be more effective than standard doses. (10µg/kg) of 
this catecholamine. 
   1-2 µg / min  - Beta 2 Stimulation 
   4 µg / min  - Beta 1stimulation 
   10-20 µg/min - Alpha & Beta 
Side effects: 
CVS effects: 
 Adrenaline stimulates beta 1 receptors to cause increased 
systolic BP, heart rate and cardiac output. There is modest decreased 
in diastolic BP reflecting vasodilatation in skeletal muscle 
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vasculature due to stimulation of beta 2 receptors.  The net effect of 
these systemic blood pressure changes are an increase in pulse 
pressure and minimal change in MAP.  Adrenaline is also increase 
the likehood of cardiac dysrhythmias. 
 Adrenaline predominantly stimulates alpha 1 receptor in skin, 
mucosa and hepatorenal vasculature producing intense 
vasoconstriction.  Renal blood flow is  substantially decreased by 
adrenaline. 
Metabolic Effects: 
Beta 1 - increase liver glycogenolysis and adipose tissue  
  lipolysis. 
Alpha1 - inhibit release of insulin 
So, these effects produce hyperglycemia 
Electrolytes: 
 Adrenaline induced hypokalemia by activation of Na-K pump 
in skeletal muscle leading to transfer K ions into cells could 
contribute to cardiac dysrhythmias. 
Ocular Effects: Adrenaline causes contraction of the radial 
muscles of iris producing mydriasis.  Contraction of orbital muscles 
produces on appearance of exophthalmus. 
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Gastrointestinal and Genitourinary effects: 
 Adrenaline produces relaxation of gastrointestinal smooth 
muscles.  Activation of beta receptors relaxes the detrusor muscle of 
the bladder, whereas activation of alpha receptor contract the trigone 
and sphincter muscles. 
Coagulation: 
 Blood coagulation is accelerated by adrenaline due to 
increased activity of factor V.  Adrenaline increases the total 
leukocyte count but at the same time causes eosinopenia. 
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1. Eledjam jj, Deschodt j et al, Canadian journal of anaesthesia 
1991; Brachial plexus block with bupivacaine: effects of added 
alpha-adrenergic agonists: comparison between clonidine and 
epinephrine. In this study, 60 patients were randomly allocated in 
two groups.  So that 30 patients received 150 micrograms of 
clonidine and 30 patients received 200 micrograms of adrenaline. In 
clonidine group there is no difference in the onset of sensory 
blockade and motor blockade compare to adrenaline. Duration of 
motor blockade prolonged in clonidine group (580.4 ± 38.7 vs 290.6 
± 34.5minutes) compare to adrenaline group. The block produced 
with addition of clonidine was longer. (994.2 + 34.2 Vs 728.3 + 35.8 
minutes) and superior to that with adrenaline. The injection of 
clonidine into the brachial plexus sheath is an attractive alternative 
to epinephrine to prolong the duration of analgesia following upper 
limb surgery under conduction anaesthesia. 
2. Dorothee M. Gaumann, et al, Anesthesia Analgesia 1992; 
74:719-725.  Clonidine Enhances the Effects of Lignocaine on C-
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Fiber Action Potential.  This study concluded that the enhancing 
effect of a low dose of clonidine (500 µM) on lignocaine induced 
(500 µM) inhibition of C-fiber AP might explain the clinical 
observation that clonidine, at approximately 1000-fold lower 
concentrations than lignocaine, prolongs the action of  lignocaine in 
peripheral nerve block.                                                                                                 
3. Dorothee Gaumann et al, Anaesthesia & Analgesia 1992               
Comparison between clonidine (150 mics) and epinephrine (200 
mics) admixture to lignocaine in brachial plexus block in this study 
suggests that the adding of  150 microgram clonidine prolong the 
duration of analgesia by > 12 hours and also useful adjuvant to those 
in whom the administration of epinephrine is contraindicated.  
4. Singelyn et al, Regional anaesthesia and pain medicine 1992;            
Adding Clonidine to Mepivacaine Prolongs the Duration of 
Anesthesia and Analgesia after Axillary Brachial Plexus Block. In 
this study 90 patients three groups divided into group A 40 ml 1% 
mepivacaine + adrenaline 200 mics, group B 40 ml 1% mepivacaine 
+ adrenaline 200 mics + S/C clonidine 150 mics, group C 40 ml 1% 
mepivacaine + adrenaline + clonidine 150 mics.  Duration of 
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anaesthesia and analgesia prolonged respectively by 37 + 6% and 
103 + 16% when compared to group A and 32 + 7% and 89+15% 
when compared to group B. One hundred fifty micrograms clonidine 
added to mepivacaine for brachial plexus block prolongs the 
duration of anesthesia and analgesia. Our results suggest that this 
effect of clonidine is local rather than systemic.  
5. FJ Singelyn et al, Anesthesia & Analgesia, 1996; A minimum 
dose of clonidine added to mepivacaine prolongs the duration of 
anesthesia and analgesia after axillary brachial plexus block.  This 
study reported that the dose of clonidine required prolonging 
significantly the duration of both anesthesia and analgesia after 
axillary brachial plexus blockade is 0.5 microgram/kg and that, at 
this dose, clonidine may be used without important reported side 
effects even in outpatients. 
6. Bernard, Jean-Marc et al,  Anaesthesiology 1997 ; Dose-Range 
Effects of Clonidine Added to Lidocaine for Brachial Plexus Block           
In this study, 3 doses of clonidine 30, 90, 300 micrograms added to 
lignocaine.  Clonidine prolonged analgesia by the mean of 770 
minutes (Range 190 to 1440 minutes) for larger doses. This study 
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suggests that a small dose of clonidine enhances the quality of the 
peripheral blocks from lignocaine and limits the classical alpha2 -
agonist side effects to sedation. 
7.    A. .El Saied, M. P. Steyn et al, Canadian Journal of 
anaesthesia 2000; Clonidine prolongs the effect of ropivacaine for 
axillary brachial plexus blockade. In this study, the clonidine 
patients shows that increased duration of sensory loss from 489 to 
628 minutes with mean difference 138 minutes, the motor blockade 
from 552 to 721 minutes with mean difference 170 minutes, 
analgesia 587 to 828 minutes with mean difference of 241 minutes. 
This study concluded that the addition of 150µg of clonidine to 
ropivacaine, for brachial plexus blockade, prolongs motor and 
sensory block and analgesia, without an increased incidence of side 
effects. 
8. Henri Iskandar, et al Anesthesia Analgesia 2001; The 
enhancement of Sensory Blockade by Clonidine Selectively added to 
Mepivacaine After Midhumeral Block. This study concluded that the 
addition of clonidine to local anesthetics prolongs the duration of 
sensory block in the nerves. Such a finding could have interesting 
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clinical applications in ambulatory or planned surgery in which 
motor function is best maintained.  
9.   W. Erlacher, C. Schuschnig, F. et al, Acta anaesthesia 2001 ;                 
The effects of clonidine on ropivacaine 0.75% in axillary 
perivascular brachial plexus block. 
10.  Wolfgang Erlacher et al, Canadian journal of anaesthesia 
2001; Clonidine as adjuvant for mepivacaine, ropivacaine and 
bupivacaine in axillary, perivascular brachial plexus block. The 
present study shows that the addition of clonidine has a different 
impact on each of the three local anesthetics investigated in terms of 
onset and duration of block. Mepivacaine group rapid onset 
compared to ropivacaine and bupivacaine group. Duration of sensory 
blockade was prolonged by clonidine only in mepivacaine and 
bupivacaine groups. The Mepivacaine + clonidine – 468 + 62 mins 
Vs mepivacaine alone - 212 + 47 mins, ropivacaine + clonidine – 
712 + 82 mins Vs ropivacaine alone - 702 + 52 mins, bupivacaine + 
clonidine – 972 + 72 mins Vs bupivacaine alone – 728 + 36 mins.  
11. Henri Iskandar et al Anesthesia Analgesia 2000; The Analgesic 
Effect of Interscalene Block Using Clonidine as an Analgesic for 
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Shoulder Arthroscopy. This study reported that Clonidine 
administered via an interscalene catheter enhanced analgesia 
compared with systemic administration. 
12.  D. Hutschala et al, European Journal of Anaesthesiology 
2004; Clonidine added to bupivacaine enhances and prolongs 
analgesia after brachial plexus block via a local mechanism in 
healthy volunteers. This study suggested that admixture of clonidine 
2mics / kg to bupivacaine 0.25% 40 ml plus epinephrine prolongs 
and enhances brachial plexus blockade by 270 minutes compared 
without clonidine.   Lower clonidine plasma concentrations for block 
treatment strongly suggest a local effect. 
13. A. Duma, B. Urbanek, et al, Br. J. anaesthesia 2005 ;         
Clonidine as an adjuvant to local anaesthetic axillary brachial plexus 
block: a randomized, controlled study.       
14. Gabriella Iohom,  et al,  Anesthesia  Analgesia 2005 ; The 
Effects of Clonidine Added to Mepivacaine for Paronychia Surgery 
Under Axillary Brachial Plexus Block. This study suggest that in the 
setting of distal infected tissue surgery under ABPB infected tissues 
are resistant to anesthesia compared with healthy areas within the 
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same nerve distribution and clonidine added to mepivacaine 
enhances both anesthesia and postoperative analgesia. 
15. Brian M. Ilfeld et al, Anaesthesia Analgesia 2003 ; Continuous 
Infraclavicular Perineural Infusion with Clonidine and Ropivacaine 
Compared with Ropivacaine Alone: A Randomized, Double-
Blinded, Controlled Study.  This study reported that clonidine is 
often added to long-acting local anesthetic perineural infusions in an 
effort to improve postoperative analgesia. 
16. Cucchiaro G, Ganesh A et al, Anaesthesia Analgesia 2007 ; The 
effects of clonidine on postoperative analgesia after peripheral nerve 
blockade in children. This study concluded that the addition of 
clonidine to bupivacaine and ropivacaine can extend sensory block 
by a few hours, and increase the incidence of motor blocks. 
17.  Popping DM, Elian et al, Anaesthesiology 2009; clonidine as 
an adjuvant to local anaestheics for peripheral nerve and plexus 
block: Meta analysis of randomized trials. This study reported that 
the clonidine prolonged the duration of post operative analgesia by 
122 minutes, sensory blockade by 74 minutes, and motor blockade 
by 41 minutes.  
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18. Nakamura M et al, European Journal of Pharmcology 1988; 
Peripheral analgesic action of clonidine: mediation by release of 
endogenous enkephalin-like substances. These studies suggest that, 
in addition to its central analgesic action, clonidine can induce 
peripheral antinociception by an alpha 2-adrenoceptor-mediated 
local release of enkephalin-like substances. 
19. Maze & Tranquil et al. Anaesthesiology 1991; Alpha-2 
adrenergic agonists role in clinical anaesthesia. This study concluded 
that clonidine has analgesic activity like a potent opioid narcotic, as 
anxiolytic & sedative as benzodiazepine, and sympatholytic & its 
action is reversible. 
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MATERIALS AND METHODS 
This study was conducted at Government Rajaji Hospital 
attached to Madurai medical college. 80 patients of ASA grade I or 
II of either sex and age more than 20 years undergoing upper limb 
surgery (mostly orthopedic and plastic surgeries )  were included. 
Patients allergic to local anaesthetics and contraindicated to 
clonidine were excluded from this study. It was double blinded study 
in which patients were randomly allocated into two groups A and B. 
Each group comprises of 40 patients, surgery was done under 
supraclavicular approach to Brachial plexus block. 
PROCEDURE 
 After ethical committee approval, informed consent was 
obtained from the patients. No premedication was given to the 
patients. Intravenous access was obtained, Anaesthesia machine 
checked, resuscitative equipments and drugs were kept ready. 
Supraclavicular block was performed by classic approach after 
eliciting paresthesia. If paresthesia is not elicited, only first rib is 
encountered excluded from this study. 
 In GROUP A: Patients received supraclavicular block with 
40ml of 0.25% Bupivacaine + 200 microgram of adrenaline.    
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 In GROUP B: Patients received supraclavicular block with       
40ml of 0.25%Bupivacaine + 150 microgram of clonidine.  
           Care was taken so that the toxic doses of the local 
anaesthetics were not exceeded according to the weight of the 
patients. 
PARAMETERS OBSERVED 
1. Onset of Analgesia  
 Onset of analgesia was taken as abolishment of pins prick pain 
over the distribution of ulnar and median and was assessed every 
minute after the performance of the block. 
2. Onset of motor blockade: 
 Onset of motor blockade was assessed every 2 minute after the 
block using four point scales 
0- Normal power  
1- Weakness but able to move arm  
2- Not able to move arm but the fingers 
3- Complete motor Blockade                                                           
Attaining a score of 2 was considered as the onset of motor Block 
3.   Duration of surgery; 
4.    Duration of motor Blockade:  
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   When (3) in the four point scale changes to (2) the motor 
blockade is said to reverse. The duration of motor block is noted 
from the time from scale (3) to scale (3). 
5.   Duration of analgesia;  
 The pain was assessed using visual Analogue scale having 
10cm length numbered from 0 to 10. Patient was explained about the 
visual Analogue scale as 0 - No pain and 10 the worst possible pain 
and was asked the score in visual analogue scale. 
 The patient was observed every 30 minutes after the surgery is 
over till the motor block reverses and thereafter hourly for 6 hrs; 2 
hourly for next 6 hrs and than of 24 hours. 
a. Duration of absolute pain free period ; the post operative 
period during which the patient did not have pain (VAS– 0) 
b. Time of which VAS score is greater than 5 is noted and 
patient was given intramuscular NSAID (Injection – 
Diclofenec) 
c. Duration of post operative analgesia;  the period of time 
after the surgery till the patient needs analgesic (VAS score 
more than 5) 
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      6. Vital parameters; 
   Pulse rate, 
   Blood pressure, 
   Respiratory rate are monitored periodically. 
7. Sedation score; 
          Brain & Ready score was employed  
0 – Fully awake 
1- Drowsy   
2- Drowsy but arousable on touch or call 
3- Drowsy but arousable on deep stimuli 
4- somnolent 
8.   Side effects noted are 
  hypotension, 
   bradycardia.  
     
   9. Patients in whom the block was unsuccessful due to total failure 
of missed dermatomes which needed intravenous supplementation or 
general anaesthesia were excluded from the study. 
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Statistical Tools;  
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2008).  
 
 Using this software range, frequencies, percentages, means, 
standard deviations, chi square and ‘p’ values were calculated. Kruskul 
Wallis chi-square test was usd to test the significance of difference 
between quantitative variables and Yate’s test for qualitative variables. A 
'p' value less than 0.05 is taken to denote significant result. 
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OBSERVATIONS AND RESULTS 
 
 This study comprised of two groups.  The patients in group A 
received 0.25% Bupivacaine 40ml + 200 microgram of adrenaline.  
In group B received 0.25% Bupivacaine 40ml + 150 microgram of 
clonidine. 
AGE & WEIGHT: 
 Age distribution in the Adrenaline group A varied from 20 
years to 72 years with mean age of 34.6 years and standard deviation 
of (15.5). 
 In clonidine group (group B) Age varied from 20 years to 65 
years with mean value of 34.9 years and standard deviation of (12.7) 
as shown in table 1 and figure 1. 
 Weight of the patients in the adrenaline group A had a mean 
value of 60.3 kg with standard deviation of 5.0.  In clonidine group 
mean value of 61.7 and standard deviation of 5.0 as shown in Table 
2 and figure 2. 
 In group A 31 patients were male and rests were female.  In 
group B 28 patients were male and rests were female. 
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Table - 1 
AGE DISTRIBUTION 
Age (yrs) Group A 
(No.of patients) 
Group B 
(No.of patients) 
20 – 30 22 17 
31 – 40 8 13 
41 – 50 3 5 
>  50 7 5 
Range (years) 20-72                           20-65  
        34.6                              34.9 
        15.5                             12.7 
 Mean(years) 
    S.D 
p value 0.5502 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table - 2 
Weight Distribution 
Weight (kgs) Group A 
(No.of patients) 
Group B 
(No.of patients) 
51 – 60 27 19 
>60 13 21 
Range ( kgs )            55-68                      52-68 
           60.3                         61.7 
           5.0                            5.0 
Mean ( kgs) 
     S.D 
P value 0.2847 
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Onset of Sensory Block: 
 Time taken for the onset of sensory blockade in group A 
(Adrenaline) varied from six minutes to a maximum of 12 minutes 
with mean values of 9.18 minutes with standard deviation of 1.55.  
In group B (clonidine) it varied from seven minutes to 12 minutes 
with mean value of 8.78 with standard deviation of 1.12 as shown 
Table 3, fig 3. 
Table – 3 
Onset of sensory Block 
 
Onset (min) 
Group A 
(No.of patients) 
Group B 
(No.of patients) 
5-7 3 4 
8-10 31 34 
11-13 6 2 
>14 0 0 
Range(minutes)           6-12                        7-12 
          9.18                         8.78 
         1.55                          1.12 
Mean (minutes) 
    S.D 
p value 0.2208 
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Onset of motor block: 
 Onset of motor block varied from 10 minutes to 18 minutes in 
the (adrenaline) group A with mean 14.13 minutes and standard 
deviation of 1.67. 
 In (clonidine) group B it varied from 10 minutes to 16 minutes 
with a mean of 13.78 minutes and standard deviation of 1.27 as 
shown in Table 4, fig 4. 
Table – 4 
Onset of Motor Blockade 
On set 
(min) 
Group A 
(No.of patients) 
Group B 
(No.of patients) 
8-10 3 1 
11-13 9 14 
14-16 27 25 
> 17 1 0 
Range(minutes)            10-18                     10-16             
           14.13                      13.78 Mean (minutes)
      S.D            1.67                         1.27 
p value 0.2362 
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Duration of Surgery: 
 The duration of surgery in group A varied from 90 minutes to 
240 min with mean of 107.0 minutes standard deviation 24.4. In 
group B, it varied from 90 minutes to 150 minutes with mean of 
113.8 minutes and standard deviation of 14.3 as shown in Table 5, 
fig 5. 
Table – 5 
Duration of Surgery 
Duration 
(min) 
Group A 
(No.of patients) 
Group B 
(No.of patients) 
60-90 12 3 
91-120 27 31 
121-150 - 6 
>  150 1 - 
Range(minutes)            90-240                     90-150 
            107.0                      113.8 
             24.4                      14.3 
Mean (minutes) 
    S.D 
p value 0.0755 
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Duration of Motor Blockade: 
 The duration of motor blockade in group A varied from 250 
minutes to a maximum of 330 minutes with a mean value of 280.75 
minutes and a standard deviation of (18.7) 
 In group B, varied from 480 minutes to 620 minutes with 
mean value of 550.8 minutes and standard deviation of (28.7) as 
shown in Table 6, fig.6. 
Table – 6 
Duration of Motor Block 
Duration 
(mins) 
Group A 
(No.of patients) 
Group B 
(No.of patients) 
250-300 30 - 
301-400 10 2 
401-500 - 36 
>500 - 2 
Range(minutes)         250-330                      480-620 
         280.75                        550.8 
         18.7                             28.7 
Mean (minutes)
    S.D 
p value 0.0001 
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Duration of absolute pain free period; 
             The post operative period during which the patient did not 
have pain (i.e VAS – 0) in group A varied from 330 minutes to a 
maximum 480 minutes with mean of 371.4 minutes and a standard 
deviation 27.5.  
           In group B it varied from 500 minutes to a maximum of 720 
minutes with mean of 643.8 minutes and standard deviation 36.6 as 
shown as table 7 and figure 7. 
Table -7 
Duration of  absolute pain free period 
Duration 
(mins) 
Group A 
(No.of patients) 
Group B 
(No.of patients) 
300-400 37 - 
401-500 3 1 
501-600 - 4 
>600 - 35 
Range(minutes)          330-480                  500-720 
Mean(minutes) 371.4                        643.8 
           27. 5                         36.6 S.D 
       p value 0.0001 
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Duration of post operative analgesia: 
 The post operative period till the patient demands systemic 
analgesic (ie. VAS score > 5) varied from 480 minutes to a 
maximum of 670 minutes in group A with a mean of 564.75 minutes 
and a standard deviation of (24.2). 
 In the group B clonidine group, it varied from 840 minutes to a 
maximum of 1080 minutes with mean of 959.3 minutes and standard 
deviation of (38.3) as shown in Table 8, fig 8. 
Table – 8 
Duration of Post operative Analgesia 
Duration 
(mins) 
Group A 
(No.of patients) 
Group B 
(No.of patients) 
400-500 4 - 
501-600 30 - 
601-900 6 4 
>900 - 36 
Range(minutes)          480-670                  840-1080  
Mean(minutes)           564.75                    959.3 
S.D             24.2                      38.3 
p value 0.0001 
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Sedation Score: 
 In group A, it was mean 0.2 + 0.1, in group B it was mean 1.7 
+ 0.51 as shown in the table 9 and figure 9. 
                                           Table – 9 
Sedation Score 
 
 
 
 
 
 
Sedation Score Group A 
(No.of patients) 
Group B 
(No.of patients) 
0 32 0 
1 8 12 
2 0 27 
3 0 1 
4 0 0 
Mean 
SD 
p value 
           0.2                          1.7 
           0.1                          0.51 
                       0.0001 
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DISCUSSION 
 
                Alpha-2 agonist like clonidine was introduced in the early 
1960s as a nasal decongestant. During its use a nasal decongestant, 
the antihypertensive property of drug was found out. Subsequently 
more insights into the pharmacological properties have led to its use 
in clinical anaesthetic practice as well. 
 
                 Clonidine assumes greater importance as anaesthetic 
adjuvant and analgesic. Its primary effect is sympatholytic.  It 
reduces peripheral norepinephrine release by stimulation of 
prejunctional inhibitory alpha-2 adrenoreceptors. It inhibits central 
neural transmission in the dorsal horn by presynaptic and 
postsynaptic mechanism and directly in spinal preganglionic 
sympathetic neurons. Traditionally it was used as antihypertensive 
drug, but uses based on sedative, anxiolytic, and analgesic properties 
are being developed. In 1988 Nakamura M et al reported that 
Peripheral analgesic action of clonidine mediated by release of 
endogenous enkephalin-like substances.  
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                 In 1991 Maze & Tranquil et al reported that Alpha-2 
adrenergic agonists has an analgesic activity like a potent opioid, is 
anxiolytic & sedative as benzodiazepine, and sympatholytic and its 
action is reversible. 
   Adjuncts to local anaesthetics for peripheral plexus blockade 
may enhance the quality and duration of anaesthesia and 
postoperative analgesia. Clonidine has central analgesic action in 
addition to its peripheral antinociception by an alpha-2 
adrenoreceptor mediated local release of encephalin like substances.  
            Clonidine enhances both sensory and motor blockade of local 
anesthetics in peripheral nerve blockade and central neuroxial 
blockade. Clonidine blocks conduction of C and A gamma fibers and 
increases potassium conductance in isolated neurons and intensifies 
the conduction of local anesthetics.  
                Clonidine may modify the action of local anaesthetics in 
the sodium channel either directly or indirectly.  
                By statistical analysis of two groups the age distribution 
in both groups was statistically not significant with a p value of 
0.5502 (p> 0.05). 
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 When comparing the weight of the patients in two groups it 
was statistically not significant with a p value of 0.7508 ( p >0.05).  
Both the groups were comparable in relation to Age and Weight. 
 Duration of surgery was also comparable in both groups with a 
p value of 0.0755 (p> 0.05). 
Onset of sensory Blockade: 
 Mean onset of sensory block in group A was 9.18 ± 1.55 
minutes and in group B, it was 8.78 ± 1.12 minutes.  The difference 
between the two groups was statistically insignificant with a p value 
of 0.2208 (p>0.05).  
Onset of motor blockade: 
 Mean onset of motor blockade in group A was 14.1 ± 1.67 
minutes and in group B it was 13.25 ± 1.37 minutes. The difference 
between the two groups was statistically insignificant with a p value 
of 0.0744(p>0.05). 
 On addition of clonidine to the local anaesthetic solution there 
is no difference in the onset of sensory and motor blockade 
compared to the adrenaline group. Eledjam JJ, Deschodt J et al study 
also reported that no difference in the onset of sensory blockade and 
motor blockade.  
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Duration of Motor Blockade: 
 Mean duration of motor block from score 3-3 in group A was 
280.75 ± 18.7 minutes and in group B 550.8 ± 28.7 minutes.  The 
difference between the two groups was statistically significant with a 
p value of 0.0001(p<0.05). 
 Addition of clonidine to local anaesthetic solution has 
significantly prolonged duration of motor blockade. These results 
correlates with studies conducted by Eledjam JJ, Deschodt J et al, in 
clonidine group it was 580.4 ± 38.7 minutes, compared to adrenaline 
group it was 290.6 ± 34.5 minutes. 
Duration of Absolute pain free period: 
 The mean duration of absolute pain free period is till the VAS 
score 0 in Group A was 371.4 + 27.5 minutes and in group B it was 
643.8 + 36.6 minutes. 
 The difference between the two groups was statistically 
significant with a p value of 0.0001 (p<0.05). 
Addition of clonidine to local anaesthetic solution prolonged the 
absolute pain free period significantly when compared to adrenaline 
group. These results also correlate with studies conducted by 
Eledjam JJ, Deschodt J et al. 
 71
Duration of post operative analgesia:   
 The mean duration of post operative analgesia is till the VAS 
score > 5 and in group A it was 564.75 ± 24.2 minutes and in group 
B it was 959.3 +38.3 minutes. 
 The difference between the two groups was statistically 
significant with a p value of 0.0001 (p<0.05). 
 Addition of clonidine to local anaesthetic solution prolonged 
the post operative analgesia significantly when compared to 
adrenaline group. These results correlate favorably with studies 
conducted by Eledjam JJ, Deschodt J et al, in clonidine group it was 
994.2 ±34.2 minutes, compared to adrenaline group it was 728.3 ± 
35.8 minutes. 
Sedation score: 
The sedation score in both groups are noted. The sedation score in 
group B it was mean 1.72 ± 0.51, in group A it was mean 0.2±0.1. In 
clonidine group since the sedation score was not more than 2, the 
respiratory function was not compromised. So intra operative 
sedation is well observed in clonidine group. 
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Side Effects: 
 Patients were observed for the side effects such as hypotension 
and bradycardia. In both groups there is no incidence of hypotension 
and bradycardia. No complications related to brachial plexus block 
were observed. 
 In this study, the addition of Clonidine to the local anaesthetic 
solution produces no difference in the onset of sensory and motor 
blockade when compared to adrenaline group.  The duration of post 
operative analgesia is significantly higher in clonidine group when 
compared to adrenaline group.  The duration of motor blockade is 
also increased in clonidine group. These inferences provide 
clonidine produces a prolonged sensory and motor blockade. 
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                                       SUMMARY 
 
 80 patients of ASA grade I or II undergoing upper limb 
surgeries were randomly assigned into two groups, Group A and B 
 Surgery was done under supraclavicular approach to brachial 
plexus block. 
 The Patients in group A received 40 ml 0.25% bupivacaine 
and 200 microgram of adrenaline. In group B received 40 ml of 
0.25% of bupivacaine and 150 micrograms clonidine. 
 Parameters observed were time of onset of sensory block and 
motor block, duration of motor blockade, duration of post operative 
analgesic, duration of absolute pain free period, sedation score and 
side effects. 
Study shows that 
1. Addition of clonidine to local anaesthetic solution shows 
no difference in the onset of sensory blockade and motor 
blockade compared to adrenaline. 
2. Addition of clonidine to local anaesthetic solution 
significantly prolongs the duration of post operative 
analgesia by 395 minutes compared to adrenaline. 
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3. Addition of clonidine to local anaesthetic solution 
increases the duration of motor blockade by 170 minutes 
compared to adrenaline. 
4. Addition of Clonidine to local anaesthetic solution 
increases the duration of absolute pain free period by 272 
minutes compared to adrenaline. 
5. In clonidine group intraoperative sedation is well 
observed without compromising respiratory function.  
6. There are no side effects like hypotension and bradycardia 
in clonidine group. 
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CONCLUSION 
 
  The addition of clonidine to local anaesthetic solution in 
supraclavicular approach to brachial plexus block prolongs the 
duration of postoperative analgesia and motor blockade, when 
compared to the adrenaline.  
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PROFORMA 
Comparison of CLONIDINE and ADRENALINE as adjuvants to 
bupivacaine in supraclavicular approach to Brachial plexus block 
 
Name:                    Age:                 Sex:                        ASA Grade : 
Address :                   Weight:             IP No : 
Diagnosis :  
Surgery :  
Investigations:  
Hb% :                                  Albumin               Blood urea -     mg% 
         Urine    Sugar -     mg% 
                                                  Sugar   creatinine -     mg% 
ECG  : X ray chest: 
Group A :    Supraclavicular block with Bupivacaine 0.25% 40 ml 
                           +200 micrograms of  adrenaline 
Group B :    Supraclavicular block with bupivacaine 0.25% 40 ml 
                           + 150 micrograms of clonidine 
OBSERVATION : 
Onset of sensory blockade : 
Onset of motor blockade : 
Duration of surgery  : 
Duration of Motor blockade : 
Duration  absolute pain free period : 
Duration of post operative analgesia : 
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Side Effects : 
Hypotension : Yes / No 
Bradycardia :  Yes / No   
 
Motor Block : 
0   - Normal power   
1   - Paresis but able to move arm 
2   -   Not able to move arm but able to move fingers 
3   -   Complete motor blockade 
 
VAS (Visual Analogue score ): 
Sedation score: 
Brain & Ready score was employed  
          0 - Fully awake 
1- Drowsy   
2- Drowsy but arousable on touch or call 
3- Drowsy but arousable on deep stimuli 
4- somnolent 
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CLONIDINE  HYDROCHLORIDE 
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BUPIVACAINE 
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1 A Mookaye  50/F II 29635 Debridment & Tendon repair 63 8 14 90 320 405 580 2 0 nil nil
2 A Thangaraj 28/M I 39395 Debridment& k wire 63 9 14 90 260 380 560 1 0 nil nil
3 A Raja 34/M I 36771 Cutinjury & Tendon repair 56 7 13 110 280 370 550 2 0 nil nil
4 A Anthoni 40/M I 42330 Rt olecranon# ORIF 68 10 14 120 270 370 480 3 1 nil nil
5 A Karthikayan 22/M I 46056 Debridment& k wire 60 9 14 100 280 360 560 2 0 nil nil
6 A Poovaye 60/F II 40322 #BB FA & ORIF 57 8 13 110 310 360 580 2 0 nil nil
7 A Selvasivam 27/M I 56317 Crush injury & Debridment 56 11 16 90 290 380 500 2 1 nil nil
8 A Sakthivel 31/M I 56314 Crush injury & Debridment 67 9 14 90 280 400 590 3 0 nil nil
9 A krishnan 55/M I 55285 # Montagia & ORIF 56 8 12 120 250 340 660 2 0 nil nil
10 A Sivakumar 23/M I 21423 Crush injury & Debridment 58 6 10 100 280 480 580 2 0 nil nil
11 A Murugan 39/M I 53977 Rt SOH # & ORIF 60 8 14 120 310 390 480 1 0 nil nil
12 A Balamurugan 29/M I 57360 Rt olecranon# ORIF 56 12 16 110 290 370 670 2 0 nil nil
13 A Pandiyan 29/M I 60853 Lt crush injury & debridment 68 10 14 90 280 380 560 2 1 nil nil
14 A Subramani 65/M II 60747 Rt crush injury & debridment 60 8 14 90 260 380 580 3 0 nil nil
15 A Swaminathan 22/M I 61916 Cutinjury & Tendon repair 55 8 14 90 280 400 660 2 0 nil nil
16 A Raju 21/M I 61145 Degloving injury &Debridmrnt 58 8 12 100 280 400 580 2 0 nil nil
17 A Palaniammal 39/F I 59338 # Rt BB FA & ORIF 66 10 14 110 260 350 520 2 0 nil nil
18 A Akilandan 20/F I 56324 Contracture Rt hand & release SSG 59 10 16 100 280 400 530 1 1 nil nil
19 A Raju 26/M I 65995 Cutinjury Rt & Tendon repair 56 12 18 90 300 410 510 1 0 nil nil
20 A Raju 30/M I 59421 Rt raw area & SSG 58 10 16 100 260 390 490 2 0 nil nil
21 A Muthukaruppan 47/M II 66054 Lt crush injury & debridment 58 8 12 100 250 380 590 2 1 nil nil
MASTER CHART  GROUP A  ‐ ADRENALINE 
22 A Kesavan 27/M I 63831 Rt ext tendon injury & Repair 67 9 15 100 320 370 580 1 0 nil nil
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23 A Beer mohamood 23/M I 68406 Rt cut injury & Tendon repair 59 8 13 100 260 380 590 1 1 nil nil
24 A Muthusamy 25/M I 74782 Lt galazi # &  ORIF 57 10 15 120 250 360 570 2 0 nil nil
25 A Duraipandi 72/M II 87188 Rt Galazei # & ORIF 57 9 14 110 310 350 560 2 0 nil nil
26 A Sophy 30/F I 87268 Rt # BB    FA & ORIF 59 8 13 110 330 360 490 2 1 nil nil
27 A Mani 65/M II 76015 Lt # SOH &  ORIF 67 12 16 120 260 340 550 3 0 nil nil
28 A Valarmathi 33/F I 72284 Rt # BB    FA & ORIF 58 10 14 120 270 350 560 3 0 nil nil
29 A Mariappan 40/M I 79332 Lt # BB FA & ORIF 58 10 16 110 290 360 570 2 1 nil nil
30 A Saravanan 20/M I 79814 Rt # SOH & ORIF 59 9 15 120 280 350 560 2 0 nil nil
31 A Palpandi 20/M I 89536 Rt # SOH & ORIF 57 12 16 120 270 340 550 2 0 nil nil
32 A Latha 26/F I 93025 Rt montagaia # ORIF 66 8 12 120 250 350 570 2 0 nil nil
33 A Kasakatha perum 31/M I 43751 Rt # SOH& vascular inj & ext fix 68 8 13 240 320 390 610 2 0 nil nil
34 A Ramesh 25/M I 62516 Lt crush injury & debridment 58 8 14 100 260 380 560 2 0 nil nil
35 A Malliga 55/F I 63528 Rt crush injury & debridment 56 10 16 90 320 360 620 3 0 nil nil
36 A krishnan 25/M I 22331 Raw area Rt hand & debrid& SSG 67 6 10 90 300 350 580 2 0 nil nil
37 A Parkani 30/F I 28451 Rt tendon injury & repair 56 10 14 100 270 360 560 3 0 nil nil
38 A Ramasamy 60/M II 25378 Lt crush injury & debridment 58 12 16 90 260 340 540 2 0 nil nil
39 A Vanniraj 50/M I 29286 Lt # BB FA & ORIF 69 10 14 90 260 330 610 2 0 nil nil
40 A Anantharaj 24/M I 28334 PBC Lt elbow & release SSG 59 9 15 110 280 340 550 2 0 nil nil
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1 B Vadukan 38/M I 37052 Lt #BB FA & ORIF 56 7 13 120 560 660 900 2 2 Nil Nil
2 B Krishnamoorthy 30/M I 37760 Rt # SOH & ORIF 67 10 15 140 550 650 920 1 2 nil nil
3 B Regina devi 21/M I 38904 Rt # olecranon & ORIF 66 9 14 110 550 670 960 2 2 nil nil
4 B Booma 38/F I 41794 Rt# lat condyle & ORIF 59 12 16 110 570 670 980 2 2 nil nil
5 B Prasath 38/M I 39553 wrist injury & Debridment 67 10 14 90 570 660 960 1 2 nil nil
6 B Ramar 54/M II 43264  Rt # lat condyle & ORIF 58 9 14 110 560 650 920 3 1 nil nil
7 B Suriyaammal 40/F I 51923 Lt # BB FA & ORIF 67 8 12 120 540 640 900 2 1 nil nil
8 B Jeyaselan 35/M I 52850 Rt # montagia & ORIF 66 10 14 110 480 500 840 2 2 nil nil
9 B Balakrishnan 45/M I 54244 Rt # SOH & ORIF 58 9 14 110 560 640 960 2 2 nil nil
10 B Prakash 36/M I 39553 Lt raw area FA & ORIF 68 8 13 100 540 600 940 1 2 nil nil
11 B vedanayam 40/M I 55672 # BB FA ORIF 58 8 15 110 550 600 950 2 1 nil nil
12 B Suseela 49/F I 57934 Lt galazi # &  ORIF 67 9 13 110 550 610 960 1 1 nil nil
13 B pandi 34/M I 34233 Rt # ulna ORIF 58 10 14 120 540 610 980 2 2 nil nil
14 B Sonai muthu 31/M I 55545 Rt ulnar nerve injury repair 68 9 15 150 550 620 1020 2 3 nil nil
15 B Ramar 50/M I 43726 Rt # SOH ext fixator 56 8 14 140 520 660 970 3 2 nil nil
16 B Abudal hasan 60/M II 42726 Rt SOH # & ORIF 60 7 13 120 500 580 970 2 1 nil nil
17 B Sivakumar 22/M I 61004 #BB FA & ORIF 65 8 14 110 480 650 950 1 2 nil nil
18 B Ramakrishanan 30/M I 522145  Rt # lat condyle & ORIF 58 10 14 110 520 660 960 2 1 nil nil
19 B Alexpandiyan 35/M I 533162 Rt # BB    FA & ORIF 64 8 14 110 520 640 950 2 1 nil nil
20 B Karthick raja 22/M I 68903 Rt ulnar nerve injury repair 59 9 13 130 620 700 1010 2 2 nil nil
MASTER CHART  GROUP B  ‐ CLONIDINE 
21 B Palaniammal 65/F II 73521 Rt crush injury hand & debridment 67 8 15 120 570 680 970 2 1 nil nil
22 B Ganesan 33/M I 73621 Rt ulna# middle 1/3& k wire 58 7 12 120 560 680 960 2 2 nil nil
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23 B Rakkammal 55/F II 74466 Lt # BB FA & ORIF 67 8 14 110 580 660 980 3 1 nil nil
24 B Durgadevi 22/F I 76802 Lt # BB FA & ORIF 52 9 13 130 560 650 970 2 2 nil nil
25 B Raja 30/M I 73960 Rt flexor tendon injury& repair 66 8 14 90 620 720 1080 1 2 nil nil
26 B palanisamy 30/M I 76114 Dislocation MCP 5thRt &ORIF 58 9 13 90 540 660 980 2 1 nil nil
27 B Karthikayan 22/M I 80268 Rt # olecranon & ORIF 66 8 14 110 550 640 960 2 2 nil nil
28 B Rangasamy 35/M I 90365 Lt extenso rtendon injury&repair 57 8 12 100 560 650 950 2 2 nil nil
29 B Natchi 35/F I 80406  Rt # BB FA & ORIF 65 9 13 110 580 660 970 3 2 nil nil
30 B Petchi 35/F I 80226 Raw area Rt hand & debrid& SSG 59 8 12 100 580 670 980 1 2 nil nil
31 B Ramu  41/F I 62986 Rt # olecranon & ORIF 65 7 10 100 550 640 950 2 2 nil nil
32 B Silambarasan 23/M I 21743Rt PTS hand& nerve& tendon repai 58 10 16 120 560 650 960 3 1 nil nil
33 B Subbulakshmi 39/F I 27678 Rt # SOH& EXT fixator 67 10 15 150 550 660 980 2 2 nil nil
34 B Ramasamy 60/M II 20672 Raw area Rt hand & debrid& SSG 57 9 14 110 580 670 1010 2 2 nil nil
35 B Alagumani 23/M I 27704 LT Raw area FA & SSG 63 8 14 100 560 660 980 1 2 nil nil
36 B Mercy gracy 30/F I 35178 Rt FA crush injury & k wire 54 9 15 100 560 650 970 1 2 nil nil
37 B Ajiskhan 24/M I 35740 Rt crush injury FA& debridment 66 10 16 110 540 650 950 1 2 nil nil
38 B Muthupandi 29/M I 34947 Rt # BB    FA & ORIF 55 11 16 120 520 610 900 1 2 nil nil
39 B Sasikumar 25/M I 40341 Delay union ulna #& ORIF 64 9 13 110 540 600 940 2 1 nil nil
40 B Panjavarnam 48/F I 35168 Lt # SOH &  ORIF 65 8 12 120 540 620 930 3 2 nil nil
